Landing
European Renal Association (ERA) 2024
Pegcetacoplan maintains early improvements in post-transplant recurrent C3G and IC-MPGN: 1-year results from the Phase II NOBLE trial
The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.